These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 35159275)

  • 1. Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives.
    Karakaş N; Üçüncüoğlu S; Uludağ D; Karaoğlan BS; Shah K; Öztürk G
    Cells; 2022 Jan; 11(3):. PubMed ID: 35159275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells.
    Generali M; Kehl D; Wanner D; Okoniewski MJ; Hoerstrup SP; Cinelli P
    J Cell Mol Med; 2022 Jan; 26(1):228-234. PubMed ID: 34821008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential roles of mesenchymal stem cells and their exosomes in the treatment of COVID-19.
    Cheng X; Jiang M; Long L; Meng J
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):948-961. PubMed ID: 34719217
    [No Abstract]   [Full Text] [Related]  

  • 4. A safety consideration of mesenchymal stem cell therapy on COVID-19.
    Cao Y; Wu H; Zhai W; Wang Y; Li M; Li M; Yang L; Tian Y; Song Y; Li J; Wang Y; Ding Q; Zhang L; Cai M; Chang Z
    Stem Cell Res; 2020 Dec; 49():102066. PubMed ID: 33242791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications.
    Chen L; Qu J; Kalyani FS; Zhang Q; Fan L; Fang Y; Li Y; Xiang C
    Cell Mol Life Sci; 2022 Feb; 79(3):142. PubMed ID: 35187617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiological Relevance of Angiotensin Converting Enzyme 2 As a Metabolic Linker and Therapeutic Implication of Mesenchymal Stem Cells in COVID-19 and Hypertension.
    Saha S; Chakrabarti S; Singh PK; Poddar J; Satapathi S; Saini S; Kakar SS; Roy P
    Stem Cell Rev Rep; 2021 Feb; 17(1):132-143. PubMed ID: 32748331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysbalance of ACE2 levels - a possible cause for severe COVID-19 outcome in COPD.
    Fließer E; Birnhuber A; Marsh LM; Gschwandtner E; Klepetko W; Olschewski H; Kwapiszewska G
    J Pathol Clin Res; 2021 Sep; 7(5):446-458. PubMed ID: 33978304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential.
    Xiong J; Bao L; Qi H; Feng Z; Shi Y
    Curr Stem Cell Res Ther; 2021; 16(2):105-108. PubMed ID: 32479246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARS-CoV-2-Infected Cells.
    Schäfer R; Spohn G; Bechtel M; Bojkova D; Baer PC; Kuçi S; Seifried E; Ciesek S; Cinatl J
    Stem Cell Reports; 2021 Mar; 16(3):419-427. PubMed ID: 32950067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MSC-extracellular vesicle microRNAs target host cell-entry receptors in COVID-19: in silico modeling for in vivo validation.
    Al Saihati HA; Dessouky AA; Salim RF; Elgohary I; El-Sherbiny M; Ali FEM; Moustafa MMA; Shaheen D; Forsyth NR; Badr OA; Ebrahim N
    Stem Cell Res Ther; 2024 Sep; 15(1):316. PubMed ID: 39304926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection.
    Avanzini MA; Mura M; Percivalle E; Bastaroli F; Croce S; Valsecchi C; Lenta E; Nykjaer G; Cassaniti I; Bagnarino J; Baldanti F; Zecca M; Comoli P; Gnecchi M
    Stem Cells Transl Med; 2021 Apr; 10(4):636-642. PubMed ID: 33188579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells.
    Hernandez JJ; Beaty DE; Fruhwirth LL; Lopes Chaves AP; Riordan NH
    J Transl Med; 2021 Apr; 19(1):149. PubMed ID: 33853637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.
    Song N; Wakimoto H; Rossignoli F; Bhere D; Ciccocioppo R; Chen KS; Khalsa JK; Mastrolia I; Samarelli AV; Dominici M; Shah K
    Stem Cells; 2021 Jun; 39(6):707-722. PubMed ID: 33586320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of Mesenchymal Stem Cell Therapy for COVID-19: A Mini Review.
    Li J; Wang X; Li N; Jiang Y; Huang H; Wang T; Lin Z; Xiong N
    Curr Gene Ther; 2020; 20(4):285-288. PubMed ID: 32867652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.
    Taghavi-Farahabadi M; Mahmoudi M; Soudi S; Hashemi SM
    Med Hypotheses; 2020 Nov; 144():109865. PubMed ID: 32562911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.
    Khoury M; Cuenca J; Cruz FF; Figueroa FE; Rocco PRM; Weiss DJ
    Eur Respir J; 2020 Jun; 55(6):. PubMed ID: 32265310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.
    Li F; Han M; Dai P; Xu W; He J; Tao X; Wu Y; Tong X; Xia X; Guo W; Zhou Y; Li Y; Zhu Y; Zhang X; Liu Z; Aji R; Cai X; Li Y; Qu D; Chen Y; Jiang S; Wang Q; Ji H; Xie Y; Sun Y; Lu L; Gao D
    Nat Commun; 2021 Feb; 12(1):866. PubMed ID: 33558541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.
    Jamshidi E; Babajani A; Soltani P; Niknejad H
    Stem Cell Rev Rep; 2021 Feb; 17(1):176-192. PubMed ID: 33432484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Menstrual Blood-Derived Mesenchymal Stem Cell Therapy for Severe COVID-19 Patients.
    Heidari F; Heidari R; Sabet MN; Hamidieh AA; Saltanatpour Z
    Curr Stem Cell Res Ther; 2024; 19(5):644-652. PubMed ID: 37073149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.